Modality
mAb
MOA
EZH2i
Target
HER2
Pathway
Notch
CFCRCRett
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Aug 2031
Phase 1Current
NCT06575473
1,594 pts·CRC
2018-02→2031-08·Not yet recruiting
NCT04961065
381 pts·CF
2019-11→2026-05·Not yet recruiting
1,975 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-262mo awayInterim· CF
2031-08-045.3y awayInterim· CRC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Not yet…
P1
Not yet…
Catalysts
Interim
2026-05-26 · 2mo away
CF
Interim
2031-08-04 · 5.3y away
CRC
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06575473 | Phase 1 | CRC | Not yet recr... | 1594 | eGFR |
| NCT04961065 | Phase 1 | CF | Not yet recr... | 381 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Tezetapinarof | CG Oncology | Phase 3 | VEGF |